25.4 C
New York
Saturday, June 13, 2026

Tag: profits

Dylan Field’s IPO Dream — Figma’s Not a Sure Bet

Dylan Field's got that deer-in-the-headlights look on him when he logs onto our Zoom call. He’s fresh off launching Figma on the NYSE, defying...

First International Bank of Israel Reports Financial Results for the Second Quarter of 2025

Reports record profits, with the financial statements reflecting accelerated growth and high profitability, whilst maintaining financial stability TEL AVIV, Israel , Aug. 11, 2025 /PRNewswire/ -- First...

60 Global Rising Stars from 1,200 Universities will Converge in Singapore for SMU’s 12th Lee Kuan Yew Competition Grand Finals

60 finalists for SG60 milestone edition selected by an international panel of judges and visionary partnersFocus on empowering Urban Solutions and Sustainability to solve...

AI Pricing: Just Guesswork with a Fancy Label

Chatbot premium subscriptions like ChatGPT Pro and Claude Max are priced around $200 a month. Nobody really knows why, but they sure hope you’ll...

America’s Next Economic Chapter Is Being Built on Land, Not Paper: Inside EX CIA strategist presentation

Washington, D.C., Aug. 09, 2025 (GLOBE NEWSWIRE) -- Ex-CIA strategist and economic advisor Jim Rickards is calling for “the return of American industry” — a silent revolution happening not in Washington, Wall Street, or Silicon Valley, but in the ground beneath America’s heartland.

Pomerantz Law Firm Announces the Filing of a Class Action Against CTO Realty Growth, Inc. and Certain Officers – CTO

NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against CTO Realty Growth, Inc. (“CTO” or the “Company”) (NYSE: CTO) and certain officers.   The class action, filed in the United States District Court for the Middle District of Florida, and docketed under 25-cv-01516, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired CTO securities between February 18, 2021 and June 24, 2025, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

Double Deposit Bonus, $50 Welcome Bonus & No-KYC 100x Leverage Trading Now Available on BexBack

SINGAPORE, Aug. 09, 2025 (GLOBE NEWSWIRE) -- With Bitcoin surpassing the $110,000 mark and stabilizing above that level, many analysts predict the cryptocurrency market will remain in a high-volatility phase for the foreseeable future. Holding spot positions may no longer yield quick profits in such a market. In response, BexBack Exchange is offering traders an unbeatable package to take advantage of these market conditions. The platform now features a 100% deposit bonus, a $50 welcome bonus for new users, and 100x leverage on cryptocurrency trading, giving investors incredible opportunities to maximize returns.

The Next Gold Boom May Not Be in Bullion–It’s in the Miners

Issued on behalf of Lake Victoria Gold Ltd. VANCOUVER, BC, Aug. 8, 2025 /PRNewswire/ -- USA News Group News Commentary – On the brink of...

The Next Gold Boom May Not Be in Bullion–It’s in the Miners

Issued on behalf of Lake Victoria Gold Ltd. VANCOUVER, BC, Aug. 8, 2025 /CNW/ -- USA News Group News Commentary – On the brink of...

The Next Gold Boom May Not Be in Bullion–It’s in the Miners

Issued on behalf of Lake Victoria Gold Ltd. VANCOUVER, BC, Aug. 8, 2025 /PRNewswire/ -- USA News Group News Commentary – On the brink of...

Salama Announces Robust H1 2025 Performance Driven by Profitability and Equity Growth

H1 2025 net profit stands at AED 8.25 million driven by profits of AED 7.86 million in the second quarter of 2025Improved equity position...

Salama Announces Robust H1 2025 Performance Driven by Profitability and Equity Growth

H1 2025 net profit stands at AED 8.25 million driven by profits of AED 7.86 million in the second quarter of 2025Improved equity position...

Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer

– Filing based on pivotal Phase 3 VERITAC-2 clinical trial demonstrating statistically significant and clinically meaningful improvement in median progression-free survival versus fulvestrant –

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsProfits